Phio Pharmaceuticals Corp has a consensus price target of $4, established from looking at the 3 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on February 6, 2024, August 16, 2023, and June 14, 2021. With an average price target of $5.33 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 481.04% upside for Phio Pharmaceuticals Corp from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|
The latest price target for Phio Pharma (NASDAQ: PHIO) was reported by HC Wainwright & Co. on February 6, 2024. The analyst firm set a price target for $4.00 expecting PHIO to rise to within 12 months (a possible 356.65% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Phio Pharma (NASDAQ: PHIO) was provided by HC Wainwright & Co., and Phio Pharma maintained their buy rating.
There is no last upgrade for Phio Pharma.
There is no last downgrade for Phio Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phio Pharma was filed on February 6, 2024 so you should expect the next rating to be made available sometime around February 6, 2025.
While ratings are subjective and will change, the latest Phio Pharma (PHIO) rating was a maintained with a price target of $6.00 to $4.00. The current price Phio Pharma (PHIO) is trading at is $0.88, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.